Literature DB >> 24125194

Production of anti-ABO blood group antibodies after minor ABO-incompatible bone marrow transplantation in NOD/SCID/gamma(c)(null) mice.

Hirofumi Tomita1, Yasushi Fuchimoto, Takehiko Mori, Jun Kato, Tomoe Uemura, Makoto Handa, Hirofumi Tazawa, Hideki Ohdan, Shinichiro Okamoto, Tatsuo Kuroda.   

Abstract

ABO incompatibility is a barrier for solid organ transplantation, but not for hematopoietic stem cell transplantation. To investigate tolerance induction, we enrolled patients who had undergone minor ABO-incompatible (O into A group, n = 6) and ABO-identical (O into O group, n = 4) bone marrow transplantation (BMT). None of the six O into A patients were positive for recipient-specific (anti-blood group A) isohemagglutinins, whereas all four O into O patients were. Peripheral blood mononuclear cells (PBMCs) were engrafted into NOD/SCID/gamma(c)(null) (NOG) mice, followed by sensitization of blood group A red blood cells. Anti-blood group A antibodies (Abs) in the sera of the patients and the human PBMC-engrafted NOG mice were measured by enzyme-linked immunosorbent assays. Anti-blood group A Abs in the patients' sera were significantly correlated with anti-A isohemagglutinin titers (p < 0.01). In the human PBMC-engrafted NOG mice, anti-blood group A Abs were significantly lower in the O into A group than in the O into O group (p < 0.05), despite ex vivo restimulation of B cells. The results of this study suggest that long after receiving minor ABO-incompatible BMT, B cells derived from newly engrafted donor precursor cells were induced tolerance to recipient-specific antigens.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell tolerance; NOD/SCID/gamma(c)(null) mice; anti-ABO blood group antibodies; isohemagglutinins; minor ABO-incompatible bone marrow transplantation

Mesh:

Substances:

Year:  2013        PMID: 24125194     DOI: 10.1111/ctr.12264

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

1.  ABO, alemtuzumab and allogeneic transplantation.

Authors:  L Cooling
Journal:  Bone Marrow Transplant       Date:  2015-04-20       Impact factor: 5.483

Review 2.  Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia.

Authors:  Viktoria Kuhn; Lukas Diederich; T C Stevenson Keller; Christian M Kramer; Wiebke Lückstädt; Christina Panknin; Tatsiana Suvorava; Brant E Isakson; Malte Kelm; Miriam M Cortese-Krott
Journal:  Antioxid Redox Signal       Date:  2017-01-18       Impact factor: 8.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.